Literature DB >> 21178056

Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map.

Andrew B Rosenkrantz1, Xiangtian Kong, Benjamin E Niver, Douglas S Berkman, Jonathan Melamed, James S Babb, Samir S Taneja.   

Abstract

OBJECTIVE: The purpose of our study was to compare the visibility of prostate cancer on trace diffusion-weighted (DW) images and the apparent diffusion coefficient (ADC) map.
MATERIALS AND METHODS: In this retrospective study, 45 patients with prostate cancer underwent preoperative MRI, including DW imaging (DWI) (b values 0, 500, and 1,000 s/mm(2)). A single observer reviewed the images in conjunction with tumor maps constructed from prostatectomy. For 132 peripheral zone (PZ) tumor foci, the visibility and contrast relative to benign PZ were recorded for T2-weighted imaging, trace DWI b500 images, trace DWI b1,000 images, and ADC maps. Trace DWI b1,000 images and ADC maps were compared in terms of Gleason score, size, normalized T2 signal intensity, ADC, and normalized ADC of visible tumors.
RESULTS: For each image set, the percentage of visible tumor foci and contrast relative to benign PZ were as follows: T2-weighted imaging, 80.3% and 0.411; trace DWI b500, 26.5% and 0.131; trace DWI b1,000, 46.2% and 0.119; and ADC maps, 62.1% and 0.309. Forty-seven tumor foci were visible on both trace DWI b1,000 images and ADC maps, 14 only on trace DWI b1,000 images, 35 only on ADC maps, and 36 on neither image set. There was no significant difference in Gleason score, size, normalized T2 signal intensity, ADC, or normalized ADC between tumors visible only on trace DWI b1,000 images and those visible only on ADC maps.
CONCLUSION: Given a greater proportion of tumors visible on the ADC map than trace DWI and greater contrast relative to benign PZ on the ADC map, we suggest that, when performing DWI of the prostate, careful attention be given to the ADC map for tumor identification.

Entities:  

Mesh:

Year:  2011        PMID: 21178056     DOI: 10.2214/AJR.10.4738

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

1.  Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection.

Authors:  Andrew B Rosenkrantz; Hersh Chandarana; Nicole Hindman; Fang-Ming Deng; James S Babb; Samir S Taneja; Christian Geppert
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

2.  Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience.

Authors:  Sung Y Park; Chan K Kim; Jung J Park; Byung K Park
Journal:  Br J Radiol       Date:  2015-12-10       Impact factor: 3.039

Review 3.  The emerging role of diffusion-weighted MRI in prostate cancer management.

Authors:  Edward M Lawrence; Vincent J Gnanapragasam; Andrew N Priest; Evis Sala
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

4.  Diffusion-weighted MR imaging in gynecologic cancers.

Authors:  Shigenobu Motoshima; Hiroyuki Irie; Takahiko Nakazono; Toshiharu Kamura; Sho Kudo
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

5.  What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T?

Authors:  T Metens; D Miranda; J Absil; C Matos
Journal:  Eur Radiol       Date:  2011-10-05       Impact factor: 5.315

6.  Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.

Authors:  A Latifoltojar; N Dikaios; A Ridout; C Moore; R Illing; A Kirkham; S Taylor; S Halligan; D Atkinson; C Allen; M Emberton; S Punwani
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-21       Impact factor: 5.554

7.  Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T.

Authors:  Ji Hyun Koo; Chan Kyo Kim; Dongil Choi; Byung Kwan Park; Ghee Young Kwon; Bohyun Kim
Journal:  Korean J Radiol       Date:  2012-12-28       Impact factor: 3.500

8.  DWI of Prostate Cancer: Optimal b-Value in Clinical Practice.

Authors:  Guglielmo Manenti; Marco Nezzo; Fabrizio Chegai; Erald Vasili; Elena Bonanno; Giovanni Simonetti
Journal:  Prostate Cancer       Date:  2014-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.